174 related articles for article (PubMed ID: 37992258)
21. Universal Germline-Genetic Testing for Breast Cancer: Implementation in a Rural Practice and Impact on Shared Decision-Making.
Shelton C; Ruiz A; Shelton L; Montgomery H; Freas K; Ellsworth RE; Poll S; Pineda-Alvarez D; Heald B; Esplin ED; Nielsen SM
Ann Surg Oncol; 2024 Jan; 31(1):325-334. PubMed ID: 37814187
[TBL] [Abstract][Full Text] [Related]
22. Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer.
Lincoln SE; Nussbaum RL; Kurian AW; Nielsen SM; Das K; Michalski S; Yang S; Ngo N; Blanco A; Esplin ED
JAMA Netw Open; 2020 Oct; 3(10):e2019452. PubMed ID: 33026450
[TBL] [Abstract][Full Text] [Related]
23. NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response Defects.
Belhadj S; Khurram A; Bandlamudi C; Palou-Márquez G; Ravichandran V; Steinsnyder Z; Wildman T; Catchings A; Kemel Y; Mukherjee S; Fesko B; Arora K; Mehine M; Dandiker S; Izhar A; Petrini J; Domchek S; Nathanson KL; Brower J; Couch F; Stadler Z; Robson M; Walsh M; Vijai J; Berger M; Supek F; Karam R; Topka S; Offit K
Clin Cancer Res; 2023 Jan; 29(2):422-431. PubMed ID: 36346689
[TBL] [Abstract][Full Text] [Related]
24. Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Among Patients With Colorectal Cancer.
Coughlin SE; Heald B; Clark DF; Nielsen SM; Hatchell KE; Esplin ED; Katona BW
JCO Precis Oncol; 2022 Nov; 6():e2200517. PubMed ID: 36370464
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.
Samadder NJ; Riegert-Johnson D; Boardman L; Rhodes D; Wick M; Okuno S; Kunze KL; Golafshar M; Uson PLS; Mountjoy L; Ertz-Archambault N; Patel N; Rodriguez EA; Lizaola-Mayo B; Lehrer M; Thorpe CS; Yu NY; Esplin ED; Nussbaum RL; Sharp RR; Azevedo C; Klint M; Hager M; Macklin-Mantia S; Bryce AH; Bekaii-Saab TS; Sekulic A; Stewart AK
JAMA Oncol; 2021 Feb; 7(2):230-237. PubMed ID: 33126242
[TBL] [Abstract][Full Text] [Related]
26. Family Matters: Germline Testing in Thoracic Cancers.
Hathaway F; Martins R; Sorscher S; Bzura A; Dudbridge F; Fennell DA
Am Soc Clin Oncol Educ Book; 2023 May; 43():e389956. PubMed ID: 37167572
[TBL] [Abstract][Full Text] [Related]
27. Germline Mutations for Novel Candidate Predisposition Genes in Sporadic Schwannomatosis.
Min BJ; Kang YK; Chung YG; Seo ME; Chang KB; Joo MW
Clin Orthop Relat Res; 2020 Nov; 478(11):2442-2450. PubMed ID: 32281771
[TBL] [Abstract][Full Text] [Related]
28. Germline Genetic Testing in Unselected Squamous and Non-Squamous Head and Neck Cancers.
Brake DA; Idler BM; Kunze KL; Golafshar MA; Heald B; Young S; Klint M; Barrus K; Esplin ED; Nussbaum RL; Samadder NJ; Hinni ML; Chang BA
Laryngoscope; 2023 Dec; 133(12):3378-3388. PubMed ID: 37132629
[TBL] [Abstract][Full Text] [Related]
29. Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study.
Uson PLS; Riegert-Johnson D; Boardman L; Kisiel J; Mountjoy L; Patel N; Lizaola-Mayo B; Borad MJ; Ahn D; Sonbol MB; Jones J; Leighton JA; Gurudu S; Singh H; Klint M; Kunze KL; Golafshar MA; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab TS; Jewel Samadder N
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e508-e528. PubMed ID: 33857637
[TBL] [Abstract][Full Text] [Related]
30. Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population.
Senda N; Kawaguchi-Sakita N; Kawashima M; Inagaki-Kawata Y; Yoshida K; Takada M; Kataoka M; Torii M; Nishimura T; Kawaguchi K; Suzuki E; Kataoka Y; Matsumoto Y; Yoshibayashi H; Yamagami K; Tsuyuki S; Takahara S; Yamauchi A; Shinkura N; Kato H; Moriguchi Y; Okamura R; Kan N; Suwa H; Sakata S; Mashima S; Yotsumoto F; Tachibana T; Tanaka M; Togashi K; Haga H; Yamada T; Kosugi S; Inamoto T; Sugimoto M; Ogawa S; Toi M
Cancer Sci; 2021 Aug; 112(8):3338-3348. PubMed ID: 34036661
[TBL] [Abstract][Full Text] [Related]
31. Universal Genetic Testing vs. Guideline-Directed Testing for Hereditary Cancer Syndromes Among Traditionally Underrepresented Patients in a Community Oncology Program.
Jones JC; Golafshar MA; Coston TW; Rao R; Wysokinska E; Johnson E; Esplin ED; Nussbaum RL; Heald B; Klint M; Barrus K; Uson PL; Nguyen CC; Colon-Otero G; Bekaii-Saab TS; Dronca R; Kunze KL; Samadder NJ
Cureus; 2023 Apr; 15(4):e37428. PubMed ID: 37181954
[TBL] [Abstract][Full Text] [Related]
32. Fanconi Anaemia, Childhood Cancer and the
Woodward ER; Meyer S
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680915
[TBL] [Abstract][Full Text] [Related]
33. Germline variants of uncertain significance, their frequency, and clinico-pathological features in a cohort of Sri Lankan patients with hereditary breast cancer.
Gunawardena K; Sirisena ND; Anandagoda G; Neththikumara N; Dissanayake VHW
BMC Res Notes; 2023 Jun; 16(1):95. PubMed ID: 37277882
[TBL] [Abstract][Full Text] [Related]
34. Detection of Pathogenic Germline Variants Among Patients With Advanced Colorectal Cancer Undergoing Tumor Genomic Profiling for Precision Medicine.
You YN; Borras E; Chang K; Price BA; Mork M; Chang GJ; Rodriguez-Bigas MA; Bednarski BK; Meric-Bernstam F; Vilar E
Dis Colon Rectum; 2019 Apr; 62(4):429-437. PubMed ID: 30730459
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial.
Shore N; Gazi M; Pieczonka C; Heron S; Modh R; Cahn D; Belkoff LH; Berger A; Mazzarella B; Veys J; Idom C; Morris D; Jayram G; Engelman A; Bukkapatnam R; Dato P; Bevan-Thomas R; Cornell R; Wise DR; Hardwick MK; Hernandez RD; Rojahn S; Layman P; Hatchell KE; Heald B; Nussbaum RL; Nielsen SM; Esplin ED
Eur Urol Oncol; 2023 Oct; 6(5):477-483. PubMed ID: 37574391
[TBL] [Abstract][Full Text] [Related]
36. Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer.
Mukherjee S; Bandlamudi C; Hellmann MD; Kemel Y; Drill E; Rizvi H; Tkachuk K; Khurram A; Walsh MF; Zauderer MG; Mandelker D; Topka S; Zehir A; Srinivasan P; Esai Selvan M; Carlo MI; Cadoo KA; Latham A; Hamilton JG; Liu YL; Lipkin SM; Belhadj S; Bond GL; Gümüş ZH; Klein RJ; Ladanyi M; Solit DB; Robson ME; Jones DR; Kris MG; Vijai J; Stadler ZK; Amos CI; Taylor BS; Berger MF; Rudin CM; Offit K
Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1450-1459. PubMed ID: 35477182
[TBL] [Abstract][Full Text] [Related]
37. Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics.
Koster R; Schipper LJ; Giesbertz NAA; van Beek D; Mendeville M; Samsom KG; Rosenberg EH; Hogervorst FBL; Roepman P; Boelens MC; Bosch LJW; van den Berg JG; Meijer GA; Voest EE; Cuppen E; Ruijs MWG; van Wezel T; van der Kolk L; Monkhorst K
Genet Med; 2024 Feb; 26(2):101032. PubMed ID: 38006283
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines.
Yap TA; Ashok A; Stoll J; Mauer E; Nepomuceno VM; Blackwell KL; Garber JE; Meric-Bernstam F
JAMA Netw Open; 2022 May; 5(5):e2213070. PubMed ID: 35594047
[TBL] [Abstract][Full Text] [Related]
39. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
40. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
